These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 34769344)

  • 1. Functional Selectivity of Dopamine D
    Yang Y
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D
    Yang Y; Lewis MM; Huang X; Dokholyan NV; Mailman RB
    Int J Biochem Cell Biol; 2022 Jul; 148():106235. PubMed ID: 35688404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.
    Conroy JL; Free RB; Sibley DR
    ACS Chem Neurosci; 2015 Apr; 6(4):681-92. PubMed ID: 25660762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role?
    Lee SM; Yang Y; Mailman RB
    J Pharmacol Exp Ther; 2014 Oct; 351(1):9-17. PubMed ID: 25052835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C.
    Lee SM; Kant A; Blake D; Murthy V; Boyd K; Wyrick SJ; Mailman RB
    Neuropharmacology; 2014 Nov; 86():145-54. PubMed ID: 24929112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biased G Protein-Independent Signaling of Dopamine D
    Guitart X; Moreno E; Rea W; Sánchez-Soto M; Cai NS; Quiroz C; Kumar V; Bourque L; Cortés A; Canela EI; Bishop C; Newman AH; Casadó V; Ferré S
    Mol Neurobiol; 2019 Oct; 56(10):6756-6769. PubMed ID: 30919214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling.
    Nishi A; Liu F; Matsuyama S; Hamada M; Higashi H; Nairn AC; Greengard P
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1322-7. PubMed ID: 12538871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of behavioral changes in T-maze alternation from dopamine D
    Cimino JX; Zhou M; Waxmonsky J; Mailman RB; Yang Y
    Psychopharmacology (Berl); 2023 Oct; 240(10):2187-2199. PubMed ID: 37578525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interactions of dopamine D1 and glutamate NMDA receptors in rat hippocampus and prefrontal cortex: involvement of ERK1/2 signaling.
    Sarantis K; Matsokis N; Angelatou F
    Neuroscience; 2009 Nov; 163(4):1135-45. PubMed ID: 19647050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing Functionally Selective Noncatechol Dopamine D
    Martini ML; Ray C; Yu X; Liu J; Pogorelov VM; Wetsel WC; Huang XP; McCorvy JD; Caron MG; Jin J
    ACS Chem Neurosci; 2019 Sep; 10(9):4160-4182. PubMed ID: 31387346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fasting biases μ-opioid receptors toward β-arrestin2-dependent signaling in the accumbens shell.
    Scheggi S; Ferrari A; Pelliccia T; Devoto P; De Montis MG; Gambarana C
    Neuroscience; 2017 Jun; 352():19-29. PubMed ID: 28391016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D1 receptor-induced signaling through TrkB receptors in striatal neurons.
    Iwakura Y; Nawa H; Sora I; Chao MV
    J Biol Chem; 2008 Jun; 283(23):15799-806. PubMed ID: 18381284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer.
    Guitart X; Navarro G; Moreno E; Yano H; Cai NS; Sánchez-Soto M; Kumar-Barodia S; Naidu YT; Mallol J; Cortés A; Lluís C; Canela EI; Casadó V; McCormick PJ; Ferré S
    Mol Pharmacol; 2014 Oct; 86(4):417-29. PubMed ID: 25097189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade.
    Chen J; Rusnak M; Luedtke RR; Sidhu A
    J Biol Chem; 2004 Sep; 279(38):39317-30. PubMed ID: 15247297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders.
    Nishi A; Shuto T
    Expert Opin Ther Targets; 2017 Mar; 21(3):259-272. PubMed ID: 28052701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel dopamine receptor signaling unit in brain: heterooligomers of D1 and D2 dopamine receptors.
    George SR; O'Dowd BF
    ScientificWorldJournal; 2007 Nov; 7():58-63. PubMed ID: 17982577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons.
    Sasaki T; Kotera J; Omori K
    J Neurochem; 2004 Apr; 89(2):474-83. PubMed ID: 15056290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opposing effects of phorbol-12-myristate-13-acetate, an activator of protein kinase C, on the signaling of structurally related human dopamine D1 and D5 receptors.
    Jackson A; Sedaghat K; Minerds K; James C; Tiberi M
    J Neurochem; 2005 Dec; 95(5):1387-400. PubMed ID: 16313517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D1-D2 receptor heteromer signaling pathway in the brain: emerging physiological relevance.
    Hasbi A; O'Dowd BF; George SR
    Mol Brain; 2011 Jun; 4():26. PubMed ID: 21663703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence against dopamine D1/D2 receptor heteromers.
    Frederick AL; Yano H; Trifilieff P; Vishwasrao HD; Biezonski D; Mészáros J; Urizar E; Sibley DR; Kellendonk C; Sonntag KC; Graham DL; Colbran RJ; Stanwood GD; Javitch JA
    Mol Psychiatry; 2015 Nov; 20(11):1373-85. PubMed ID: 25560761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.